Outcome of Myeloma Patients with COVID-19 on Active Lenalidomide-Based Therapy: Does Lenalidomide Protect From Severe COVID-19?

Hematol Oncol Stem Cell Ther. 2023 Jan 12;16(1):88-90. doi: 10.1016/j.hemonc.2020.08.002.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • COVID-19*
  • Dexamethasone / therapeutic use
  • Humans
  • Lenalidomide / therapeutic use
  • Multiple Myeloma* / complications
  • Multiple Myeloma* / drug therapy

Substances

  • Lenalidomide
  • Dexamethasone